*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Suvorexant is a <strong>dual orexin receptor antagonist</strong> developed for insomnia treatment. Synthesized via advanced organic coupling, its molecular formula is <strong>C25H28ClF4N7O2</strong> with CAS <strong>1049586-46-2</strong>.</p>
<h3>Application</h3>
<ul>
<li><strong>Pharmaceutical Manufacturing:</strong> Bulk API production for sedative formulations.</li>
<li><strong>Research & Development:</strong> Clinical trials targeting sleep-wake cycle disorders.</li>
<li><strong>Distribution:</strong> Supply to hospitals and specialized clinics for patient therapy.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly contraindicated in narcolepsy; requires controlled storage below 25°C. Handle with PPE due to potential respiratory sensitization and CNS depression risks during synthesis.</p>